-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lepzacitinib in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lepzacitinib in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lepzacitinib in Atopic Dermatitis (Atopic Eczema) Drug Details: ATI-1777 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Luveltamab Tazevibulin in Fallopian Tube Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Luveltamab Tazevibulin in Fallopian Tube Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Luveltamab Tazevibulin in Fallopian Tube Cancer Drug Details: STRO-002 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cusatuzumab in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cusatuzumab in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cusatuzumab in Acute Myelocytic Leukemia (AML, Acute...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tipifarnib in Anaplastic Large Cell Lymphoma (ALCL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tipifarnib in Anaplastic Large Cell Lymphoma (ALCL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tipifarnib in Anaplastic Large Cell Lymphoma (ALCL) Drug Details:...
-
Company Insights
Innovation and Patenting activity of ATI Inc Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of ATI Inc Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATI-2138 in Arthritis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ATI-2138 in Arthritis Drug Details: ATI-2138 is under development for the treatment of psoriasis, inflammatory...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATI-2138 in Dermatosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ATI-2138 in Dermatosis Drug Details: ATI-2138 is under development for the treatment of psoriasis, inflammatory...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATI-2173 in Hepatitis B
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATI-2173 in Hepatitis B report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATI-2138 in Inflammatory Bowel Disease
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ATI-2138 in Inflammatory Bowel Disease Drug Details: ATI-2138 is under development for the treatment of...